

Ready to start planning your care? Call us at [800-525-2225](tel:800-525-2225) to make an appointment.

×



Memorial Sloan Kettering
Cancer Center

[Make an Appointment](#)

[← Back](#)

HUMAN ONCOLOGY & PATHOGENESIS PROGRAM

[Patient & Family Resources](#)

[Refer a Patient](#)

The Ingo Mellinghoff Lab

ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Equality, diversity & inclusion](#)

[Annual report](#)

[Give to MSK](#)



Ingo K. Mellinghoff, MD, FACP

Our laboratory focuses on the study of molecular pathways that regulate brain tumor growth. Our long-term goal is to develop therapeutic paradigms that target specific properties of primary brain tumors, including genetic alterations in cancer signaling pathways, unique aspects of brain tumor metabolism, or interactions of brain tumor cells with their brain microenvironment. Our studies in experimental brain tumor models are closely linked to the evaluation of novel agents in early-phase clinical trials.



Featured News



[Experimental Drug for Low-Grade Glioma With IDH Gene Mutation Shows Promise](#)

A new experimental drug could be an effective treatment for some people with low-grade glioma.



[Treatment for Low-Grade Glioma Advances to Phase 3 Clinical Trial](#)

According to findings from a research team led by study first-author Ingo Mellinghoff, MD, Chair of MSK's Department of Neurology: vorasidenib and ivosidenib reduced concentrations of 2-HG by more than 90%, were well-tolerated, and showed encouraging tumor responses amongst 49 patients enrolled in a multisite trial between April 2019 and April 2020. Vorasidenib showed greater brain penetration than ivosidenib. Based on the phase 1 trial results, vorasidenib was advanced to a phase 3 trial.

IN THE CLINIC



[Analyzing Spinal Fluid Could Guide Brain Tumor Diagnosis and Treatment](#)

Cancer DNA taken from spinal fluid could serve as a liquid biopsy that provides information on brain tumor mutations.

[View All Featured News](#)

Publications Highlights

[Mellinghoff IK, Lu M, Wen PY, Taylor JW, Maher EA, Arrillaga-Romany I, Peters KB, Ellingson BM, Rosenblum MK, Chun S, Le K, Tassinari A, Choe S, Toubouti Y, Schoenfeld S, Pandya SS, Hassan I, Steelman L, Clarke JL, Cloughesy TF. Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial. Nat Med. 2023 Feb 23. doi: 10.1038/s41591-022-02141-2.](#)

[Glioblastoma and Other Primary Brain Malignancies in Adults: A Review. Schaff LR, Mellinghoff IK. Glioblastoma and Other Primary Brain Malignancies in Adults: A Review. JAMA. 2023 Feb 21;329\(7\):574-587. doi: 10.1001/jama.2023.0023.](#)

[Pourmaleki M, Jones CJ, Ariyan CE, Zeng Z, Pirun M, Navarrete DA, Li Y, Zhang M, Nandakumar S, Campos C, Nadeem S, Klimstra DS, Temple-Oberle CF, Brenn T, Lipson EJ, Schenk KM, Stein JE, Taube JM, White MG, Traweck R, Wargo JA, Kirkwood JM, Gasmi B, Goff SL, Corwin AD, McDonough E, Ginty F, Callahan MK, Schietinger A, Socci ND, Mellinghoff IK, Hollmann TJ. Tumor MHC Class I Expression Associates with Intratumoral IL2 Response in Melanoma. Cancer Immunol Res. 2022 Mar 1;10\(3\):303-313. doi: 10.1158/2326-6066.CIR-21-1083.](#)

[Tang CP, Clark O, Ferrarone JR, Campos C, Lalani AS, Chodera JD, Intlekofer AM, Elemento O, Mellinghoff IK. GCN2 kinase activation by ATP-competitive kinase inhibitors. Nat Chem Biol. 2022 Feb;18\(2\):207-215. doi: 10.1038/s41589-021-00947-8. Epub 2021 Dec 23.](#)

[Miller AM, Shah RH, Pentsova EI, Pourmaleki M, Briggs S, Distefano N, Zheng Y, Skakodub A, Mehta SA, Campos C, Hsieh WY, Selcuklu SD, Ling L, Meng F, Jing X, Samoila A, Bale TA, Tsui DWY, Grommes C, Viale A, Souweidane MM, Tabar V, Brennan CW, Reiner AS, Rosenblum M, Panageas KS, DeAngelis LM, Young RJ, Berger MF, Mellinghoff](#)

[IK. Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. Nature. 2019 Jan;565\(7741\):654-658. doi: 10.1038/s41586-019-0882-3. Epub 2019 Jan 23.](#)

[View All Publications](#)

People



Ingo K. Mellinghoff, MD, FACP

Physician-scientist Ingo Mellinghoff studies signal transduction alterations in primary brain tumors.

MD, Technical University Munich (Germany)

[646-888-2766](#)

Office Phone

[View physician profile](#)

Physician profile

Members



Smrutiben Mehta
Research Assistant



Charli Hertz
Research Technician

**Brian
Greenstein**
Research Technician

Marlene Tartaro
Research Technician



Maryam Pourmaleki
Graduate Student

**Annalisa V.
Ferrotta**
Graduate Student



**Arianna Izawa-
Ishiguro**
Pharmacology PhD
Graduate Student

Lab Alumni
+

Lab Affiliations
+

Achievements

Neuro-Oncology Scientific Award, American Academy of Neurology (2023)
Member, Association of American Physicians (2020)
Member, American Society of Clinical Investigation (2013)
Advanced Clinical Research Award, American Society of Clinical Oncology (2009)
Clinical Scientist Development Award, Doris Duke Charitable Foundation (2008)

[Read more](#)

Open Positions


To learn more about available postdoctoral opportunities, please visit our [Career Center](#)


To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit [Resources for Postdocs](#)


Career Opportunities

[Apply now](#) →

Get in Touch

 [646-888-2766](tel:646-888-2766)
Office Phone

 [646-888-2732](tel:646-888-2732)
Office Fax

 [646-888-2784](tel:646-888-2784)
Lab Phone

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Ingo K. Mellinghoff discloses the following relationships and financial interests:

American Society of Clinical Oncology (ASCO)

Professional Services and Activities

Black Diamond Therapeutics, Inc.

Professional Services and Activities

Doris Duke Charitable Foundation

Professional Services and Activities

Roche

Professional Services and Activities

Servier

Professional Services and Activities

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies [here](#). For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.

[View all disclosures](#) →

▼ Connect

[Contact us](#)

[Locations](#)

APPOINTMENTS

[800-525-2225](#)

▼ About MSK

[About us](#)

[Careers](#)

[Giving](#)

▼ Cancer Care

[Adult cancer types](#)

[Child & teen cancer types](#)

[Integrative medicine](#)

[Nutrition & cancer](#)

[Find a doctor](#)

▼ Research & Education

[Sloan Kettering Institute](#)

[Gerstner Sloan Kettering Graduate School](#) 

[Graduate medical education](#)

[MSK Library](#) 

[Communication preferences](#)

[Cookie preferences](#)

[Legal disclaimer](#)

[Accessibility statement](#)

[Privacy policy](#)

[Price transparency](#)

[Public notices](#)

© 2024 Memorial Sloan Kettering Cancer Center